These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23909006)

  • 21. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.
    Barrett FS; Carbonaro TM; Hurwitz E; Johnson MW; Griffiths RR
    Psychopharmacology (Berl); 2018 Oct; 235(10):2915-2927. PubMed ID: 30062577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
    Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered states: psychedelics and anesthetics.
    Icaza EE; Mashour GA
    Anesthesiology; 2013 Dec; 119(6):1255-60. PubMed ID: 24061599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psilocybin occasioned mystical-type experiences.
    James E; Robertshaw TL; Hoskins M; Sessa B
    Hum Psychopharmacol; 2020 Sep; 35(5):e2742. PubMed ID: 32573835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Consumption of psilocybin-containing hallucinogenic mushrooms by young people].
    Lassen JF; Lassen NF; Skov J
    Ugeskr Laeger; 1992 Sep; 154(39):2678-81. PubMed ID: 1413197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
    Garcia-Romeu A; Griffiths RR; Johnson MW
    Curr Drug Abuse Rev; 2014; 7(3):157-64. PubMed ID: 25563443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment.
    Turton S; Nutt DJ; Carhart-Harris RL
    Curr Drug Abuse Rev; 2014; 7(2):117-27. PubMed ID: 25563444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of psilocybin on time perception and temporal control of behaviour in humans.
    Wittmann M; Carter O; Hasler F; Cahn BR; Grimberg U; Spring P; Hell D; Flohr H; Vollenweider FX
    J Psychopharmacol; 2007 Jan; 21(1):50-64. PubMed ID: 16714323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alterations of consciousness and mystical-type experiences after acute LSD in humans.
    Liechti ME; Dolder PC; Schmid Y
    Psychopharmacology (Berl); 2017 May; 234(9-10):1499-1510. PubMed ID: 27714429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Between prohibitions: patterns and meanings of magic mushroom use in the UK.
    Riley SC; Blackman G
    Subst Use Misuse; 2008; 43(1):55-71. PubMed ID: 18189205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
    MacLean KA; Johnson MW; Griffiths RR
    J Psychopharmacol; 2011 Nov; 25(11):1453-61. PubMed ID: 21956378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression.
    Lyons T; Carhart-Harris RL
    J Psychopharmacol; 2018 Jul; 32(7):811-819. PubMed ID: 29338538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
    Bogenschutz MP; Forcehimes AA; Pommy JA; Wilcox CE; Barbosa PC; Strassman RJ
    J Psychopharmacol; 2015 Mar; 29(3):289-99. PubMed ID: 25586396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of hallucinogens in Slovakia: Does it differ from global trends?
    Lukačovič M; Masaryk R
    Int J Drug Policy; 2021 Dec; 98():103385. PubMed ID: 34364200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment.
    Burdick BV; Adinoff B
    Am J Drug Alcohol Abuse; 2013 Sep; 39(5):291-7. PubMed ID: 23968172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations.
    Kometer M; Pokorny T; Seifritz E; Volleinweider FX
    Psychopharmacology (Berl); 2015 Oct; 232(19):3663-76. PubMed ID: 26231498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis.
    Crowe M; Manuel J; Carlyle D; Lacey C
    Int J Ment Health Nurs; 2023 Aug; 32(4):1025-1037. PubMed ID: 36779424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin.
    Lebedev AV; Lövdén M; Rosenthal G; Feilding A; Nutt DJ; Carhart-Harris RL
    Hum Brain Mapp; 2015 Aug; 36(8):3137-53. PubMed ID: 26010878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Psilocybin-Telomere Hypothesis: An empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging.
    Germann CB
    Med Hypotheses; 2020 Jan; 134():109406. PubMed ID: 31634774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.